VivoGenie Anti-Human CD20 (Obinutuzumab) - Fc Reduced Biosimilar (IVMB0531)
- SKU:
- IVMB0531
- Antibody Type:
- In Vivo Biosimilar
- Endotoxin Level:
- Low Endotoxin
- Applications:
- In Vivo
- Disease Area:
- B-Cell Lymphomas
- Disease Area:
- Autoimmune Diseases
Description
| Product Name: | Anti-Human CD20 (Obinutuzumab) |
| SKU: | IVMB0531 |
| Size: | 500 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | GA101 |
| Target: | CD20 |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | ELISA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Muted |
| Synonyms: | Obinutuzumab, CD20, MS4A1, 949142-50-1 |
| Product Concentration: | ≥ 5.0 mg/ml |
| Purity: | ≥95% by SDS Page |
| Immunogen: | Human lymphoblastoid cell line SB. |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Antigen Distribution: | CD20 is a general B cell marker expressed by the majority of normal B cells in all stages of their development as well as by most B cell malignancies. |
| Formulation: | This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Specificity: | Obinutuzumab (GA101) activity is directed against human CD20. |
| Additional Applications Reported In Literature: | ELISA FA FC IP WB |
CD20 is a nonglycosylated 33-37 kDa phosphoprotein member of the MS4A family which is widely expressed on normal B cell surfaces during all stages of development as well as by most B cell malignancies1,2. The biological role of CD20 remains poorly understood; however, it is thought to be involved in calcium ion influx. CD20 has no natural ligand and is not immediately internalized upon antibody binding. Thus, mAbs directed against CD20 depend on the recruitment of a host response. Anti-CD20 mAbs bind to the 44 amino acid extracellular portion.
Obinutuzumab (GA101) is a new generation, type II, anti-CD20 antibody2. Obinutuzumab was humanized by grafting the complementarity-determining sequences of murine IgG1-κ antibody B-Ly1 onto human VH and VL acceptor frameworks3. The Fc segment was glycoengineered to attach bisected, complex, nonfucosylated oligosaccharides to asparagine 297, leading to increased affinity to FcgRIII.
Obinutuzumab causes homotypic adhesion4,5,6, induces direct cell death via largely caspase-independent mechanisms4,6,7,8,9, does not localize into lipid rafts4,10,11, displays half-maximal CD20 binding at saturating conditions7, and displays minimal complement dependent cytotoxicity7.
Compared to rituximab, obinutuzumab recognizes a distinct but overlapping CD20 epitope, in a different orientation that results in increased pro-apoptotic potential12,13,14. A modified elbow-hinge residue, characterized by a leucine to valine mutation at Kabat position 11, is key to superior phosphatidylserine exposure and cell death relative to rituximab3.
| Ligand/Receptor: | Src family tyrosine kinases, MHC class I, II, CD53, CD81, CD82 |
| State of Matter: | Liquid |
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Product Preparation: | Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Pathogen Testing: | To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. |
| Storage and Handling: | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| UniProt: | P11836 |
| Research Area: | Biosimilars |
Related Products
VivoGenie Anti-Human CD20 (Obinutuzumab) Biosimilar (IVMB0526)
VivoGenie Anti-Human CD20 (Obinutuzumab) - FITC Biosimilar (IVMB0532)
VivoGenie Anti-CD20 (Rituximab) Biosimilar (Fc Reduced) (IVMB0243)
Anti-Human CD20 (Obinutuzumab) - Biotin Biosimilar (IVMB0533)
